This content is from: Features

How is non-obviousness in improvement drug invention patents assessed?

Wu Xiaoping and Hu Honghui of Wanhuida examine the methodology employed by the Patent Reexamination Board to determine non-obviousness of an improvement invention

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial